Payment overview · 2025
General Payments
$8,021.43
108 reported records · 27 companies
Healthcare provider profile · identity verified
Amit Navinchandra Amin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · LAFAYETTE, LA · NPI 1144458027
Verified facts
What the public records show
CMS Open Payments records show Amit Navinchandra Amin, M.D. received $8,021.43 in general payments during 2025 across 108 reported records.
Penumbra, Inc. accounted for 33.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 424 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 274 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $2,709.76 | 33.8% | 4 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $1,052.86 | 13.1% | 6 | 2025 |
| Infraredx, Inc. | Unresolved — no canonical attribution shown | $1,000.00 | 12.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $483.28 | 6.0% | 10 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $384.90 | 4.8% | 15 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $339.72 | 4.2% | 6 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $318.59 | 4.0% | 7 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $286.32 | 3.6% | 13 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $281.97 | 3.5% | 8 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $236.03 | 2.9% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $193.24 | 2.4% | 9 | 2025 |
| Inquis Medical, Inc. | Unresolved — no canonical attribution shown | $142.28 | 1.8% | 2 | 2025 |
| Avantec Vascular Corporation | Unresolved — no canonical attribution shown | $125.00 | 1.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $96.93 | 1.2% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $71.81 | 0.9% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $67.00 | 0.8% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $34.76 | 0.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$32.72 | 0.4% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $23.32 | 0.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.62 | 0.3% | 1 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $21.48 | 0.3% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $17.19 | 0.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.70 | 0.2% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $15.83 | 0.2% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $15.83 | 0.2% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $15.81 | 0.2% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $15.48 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,910.43 | 104 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,400.00 | 1 |
| Consulting Fee | $1,000.00 | 1 |
| Travel and Lodging | $711.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $2,709.76 | 4 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $502.40 | 1 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $318.59 | 7 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $318.59 | 7 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $286.32 | 13 | 2025 |
Source payment records
|
|||||
| Other Rental Normalized: other rental |
Device | Philips North America LLC | $230.29 | 5 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $229.27 | 6 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK CORONARY Normalized: diamondback coronary |
Device | Abbott Laboratories | $228.38 | 4 | 2025 |
Source payment records
|
|||||
| VENACURE 1470 PRO Normalized: venacure 1470 pro |
Device | AngioDynamics, Inc. | $197.04 | 3 | 2025 |
Source payment records
|
|||||
| Venclose Maven Catheter Normalized: venclose maven catheter |
Device | Bard Peripheral Vascular, Inc. | $186.70 | 2 | 2025 |
Source payment records
|
|||||
| Aventus Normalized: aventus |
Device | Inquis Medical, Inc. | $142.28 | 2 | 2025 |
Source payment records
|
|||||
| AZUR CX DETACHABLE Normalized: azur cx detachable |
Device | Terumo Medical Corporation | $137.03 | 1 | 2025 |
Source payment records
|
|||||
| GLIDEWIRE Normalized: glidewire |
Device | Terumo Medical Corporation | $137.03 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROGLIDE Normalized: perclose proglide |
Device | Abbott Laboratories | $127.55 | 2 | 2025 |
Source payment records
|
|||||
| Venovo Normalized: venovo |
Device | Bard Peripheral Vascular, Inc. | $108.49 | 2 | 2025 |
Source payment records
|
|||||
| GLIDESHEATH SLENDER Normalized: glidesheath slender |
Device | Terumo Medical Corporation | $99.00 | 1 | 2025 |
Source payment records
|
|||||
| R2P MISAGO Normalized: r2p misago |
Device | Terumo Medical Corporation | $99.00 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $92.22 | 2 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $83.67 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $71.81 | 4 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $59.01 | 1 | 2025 |
Source payment records
|
|||||
| IV Other Normalized: iv other |
Device | Philips North America LLC | $58.75 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $54.50 | 3 | 2025 |
Source payment records
|
|||||
| PRODIGY CATHETER Normalized: prodigy catheter |
Device | Imperative Care, Inc | $52.70 | 2 | 2025 |
Source payment records
|
|||||
| Ranger Normalized: ranger |
Device | Boston Scientific Corporation | $43.04 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.43 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $34.76 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $32.72 | 1 | 2025 |
Source payment records
|
|||||
| Encore Normalized: encore |
Device | Philips North America LLC | $30.07 | 1 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $26.28 | 2 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| SYNERGY ABLATION SYSTEM Normalized: synergy ablation system |
Device | AtriCure, Inc. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| SUPERA Normalized: supera |
Device | Abbott Laboratories | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| LM Undivided Normalized: lm undivided |
Device | Philips North America LLC | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $17.19 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| Technical Education MRI Normalized: technical education mri |
Device | Philips North America LLC | $12.09 | 1 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $8.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
424 | 78 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
274 | 53 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 688 | 178 |
| Atorvastatin Calcium | Atorvastatin Calcium | 645 | 170 |
| Metoprolol Succinate | Metoprolol Succinate | 601 | 139 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 582 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 481 | 123 |
| Carvedilol | Carvedilol | 457 | 98 |
| Eliquis | Apixaban | 424 | 78 |
| Lisinopril | Lisinopril | 354 | 79 |
| Furosemide | Furosemide | 344 | 102 |
| Losartan Potassium | Losartan Potassium | 283 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 278 | 70 |
| Entresto | Sacubitril/Valsartan | 274 | 53 |
| Xarelto | Rivaroxaban | 246 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 186 | 45 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 183 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 155 | 40 |
| Clonidine Hcl | Clonidine Hcl | 133 | 36 |
| Ezetimibe | Ezetimibe | 128 | 32 |
| Nifedipine Er | Nifedipine | 127 | 27 |
| Repatha Sureclick | Evolocumab | 117 | 26 |
| Spironolactone | Spironolactone | 105 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 32 |
| Farxiga | Dapagliflozin Propanediol | 90 | 16 |
| Diazepam | Diazepam | 83 | 57 |
| Irbesartan | Irbesartan | 78 | 20 |
| Valsartan | Valsartan | 77 | 21 |
| Potassium Chloride | Potassium Chloride | 73 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 72 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 68 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 65 | suppressed |
| Ranolazine Er | Ranolazine | 58 | 11 |
| Warfarin Sodium | Warfarin Sodium | 58 | 14 |
| Simvastatin | Simvastatin | 56 | 18 |
| Cilostazol | Cilostazol | 55 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 54 | 14 |
| Nitroglycerin | Nitroglycerin | 53 | 27 |
| Brilinta | Ticagrelor | 48 | 13 |
| Enalapril Maleate | Enalapril Maleate | 48 | 11 |
| Atenolol | Atenolol | 47 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 13 |
| Sotalol | Sotalol Hcl | 43 | 11 |
| Fenofibrate | Fenofibrate | 39 | suppressed |
| Lovastatin | Lovastatin | 39 | suppressed |
| Praluent Pen | Alirocumab | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | 11 |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 31 | 21 |
| Torsemide | Torsemide | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Gabapentin | Gabapentin | 20 | suppressed |
| Metolazone | Metolazone | 20 | 13 |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Omeprazole | Omeprazole | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $8,021.43 · 108 records | Penumbra, Inc. | AFREZZA, ALPHAVAC, ARTIX MT, AURYON LASER SYSTEM 100-120 VAC, AZUR CX DETACHABLE, Assure WCD, Aventus, CAMZYOS, DIAMONDBACK CORONARY, ELUVIA, ENDOCROSS Device, ESPRIT, EVKEEZA, Encore, FUROSCIX, GLIDESHEATH SLENDER, GLIDEWIRE, IGT Devices Undivided, INSPIRE, IV Other, Indigo System, LEQVIO, LM Undivided, Labosys, LifeVest, Other Rental, Ozempic, PERCLOSE PROGLIDE, PERCLOSE PROSTYLE, PRODIGY CATHETER, R2P MISAGO, Ranger, RotarexS 6 F x 135 cm, SUPERA, SYMPHONY CATHETER, SYMPLICITY G3, SYNERGY ABLATION SYSTEM, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Technical Education MRI, Torus Stent Graft System, VENACURE 1470 PRO, Venclose Maven Catheter, Venovo, Wegovy, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error